- Home
- ARVN vs SVRA Comparison
ARVN vs SVRA Comparison
Compare ARVN & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- SVRA
- Stock Information
- Founded
- ARVN 2015
- SVRA N/A
- Country
- ARVN United States
- SVRA United States
- Employees
- ARVN N/A
- SVRA 59
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- ARVN Health Care
- SVRA Health Care
- Exchange
- ARVN Nasdaq
- SVRA Nasdaq
- Market Cap
- ARVN 438.1M
- SVRA 505.8M
- IPO Year
- ARVN 2018
- SVRA N/A
- Fundamental
- Price
- ARVN $9.12
- SVRA $3.25
- Analyst Decision
- ARVN Buy
- SVRA Buy
- Analyst Count
- ARVN 15
- SVRA 6
- Target Price
- ARVN $31.86
- SVRA $8.83
- AVG Volume (30 Days)
- ARVN 2.8M
- SVRA 887.3K
- Earning Date
- ARVN 05-06-2025
- SVRA 05-08-2025
- Dividend Yield
- ARVN N/A
- SVRA N/A
- EPS Growth
- ARVN N/A
- SVRA N/A
- EPS
- ARVN N/A
- SVRA N/A
- Revenue
- ARVN $263,399,999.00
- SVRA N/A
- Revenue This Year
- ARVN N/A
- SVRA N/A
- Revenue Next Year
- ARVN N/A
- SVRA N/A
- P/E Ratio
- ARVN N/A
- SVRA N/A
- Revenue Growth
- ARVN 235.54
- SVRA N/A
- 52 Week Low
- ARVN $5.94
- SVRA $2.26
- 52 Week High
- ARVN $37.38
- SVRA $5.31
- Technical
- Relative Strength Index (RSI)
- ARVN 52.04
- SVRA 65.20
- Support Level
- ARVN $5.94
- SVRA $2.85
- Resistance Level
- ARVN $6.86
- SVRA $3.05
- Average True Range (ATR)
- ARVN 0.55
- SVRA 0.19
- MACD
- ARVN 0.58
- SVRA 0.04
- Stochastic Oscillator
- ARVN 93.47
- SVRA 99.29
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.